Intravenous (IV)
Iron Drugs Market
Intravenous (IV) Iron Drugs Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Intravenous (IV) Iron Drugs Market Size and Growth
The Intravenous (IV) Iron Drugs market is experiencing robust growth, driven by increasing prevalence of iron deficiency anemia and enhanced product offerings. The global market size reached approximately $3.5 billion in 2023, with projections indicating continued expansion due to rising awareness and advancements in formulation efficiency and delivery methods.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Sanofi US
◍ Allergan
◍ AMAG Pharmaceuticals
◍ Dalichi Sankyo
◍ Luitpold Pharmaceuticals
◍ Pharmacosmos
◍ Takeda Pharmaceutical
The Intravenous (IV) Iron Drugs Market features companies like Sanofi US, Allergan, AMAG Pharmaceuticals, Daiichi Sankyo, Luitpold Pharmaceuticals, Pharmacosmos, and Takeda Pharmaceutical. These firms drive market growth through innovative formulations, robust marketing strategies, and expanding therapeutic applications, enhancing patient access and treatment outcomes globally.
Sales revenue figures:
- AMAG Pharmaceuticals: $162 million
- Takeda Pharmaceutical: $18.2 billion
- Sanofi: $10.5 billion (pharmaceuticals segment)
- Allergan: $15.7 billion
Request Sample Report
